Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Indocin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Indomethacin 75mg ER Capsules |
| 2 | ACTIVE_COMPARATOR | Indocin 75mg SR Capsules |
| Name | Type | Description |
|---|---|---|
| Indomethacin 75mg Extended-Release Capsules, Sandoz | DRUG | - |
| Indocin 75mg SR Capsules | DRUG | - |
Inclusion Criteria: * No clinically significant abnormal findings on physical exam, medical history or clinical laboratory results on screening Exclusion Criteria: * Positive test results for HIV or hepatitis B or C * No allergies to indomethacin or related drugs
Indocin is used for inflammation. It is a small molecule drug being developed by Novartis AG for the treatment of inflammation, which falls under the therapeutic area of immunology. The drug is currently in Phase 1 clinical development.
Indocin is developed by Novartis AG, a company traded under the ticker symbol NVS. The drug is a small molecule being investigated for the treatment of inflammation. It is currently in Phase 1 clinical development.
Indocin is in Phase 1 clinical development. It is an investigational drug being studied for the treatment of inflammation. The drug has completed one Phase 1 trial, and it is not yet approved by regulatory authorities.
Indocin has one completed clinical trial, NCT00858195, titled 'A Relative Bioavailability Study of 75mg Indomethacin Extended-Release Capsules'. This Phase 1 trial enrolled 36 participants and was an active-controlled, randomized study involving healthy volunteers.
Indocin is a brand name for indomethacin. The clinical trial NCT00858195 studied 75mg indomethacin extended-release capsules, which are the formulation of Indocin. The drug is being developed by Novartis AG for inflammation.